
Opinion|Videos|February 14, 2025
Strategies for Loading Dose Sse for Treatment-Naive and Switch Patients
Panelists discuss how loading doses remain crucial for treatment-naive patients to achieve rapid disease control, while patients switching therapies may require modified approaches based on their prior treatment response and disease activity.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How strictly do you adhere to the loading dose recommendations for new therapies in treatment-naive patients with neovascular age-related macular degeneration and diabetic macular edema?
- How about for patients who are switching therapies?
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
FLORetina 2025: Navigating antithrombotic therapy in wet AMD
2
FLORetina 2025: Remotely managing patients with neovascular age-related macular degeneration
3
FLORetina 2025: Multimodal deep learning for CKD diagnosis using retinal images and urine dipstick data
4
FLORetina 2025: Port delivery system shows reliable 6-month durability and sustained efficacy in neovascular AMD for up to 7 years
5














































